Moderate-to-Severe Plaque Psoriasis Pipeline Assessment | Insights into the Current Therapies, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Outlook | Key Companies - Bristol Myers Squibb (Sotyktu™ (deucravacitinib)

As per DelveInsight's assessment, globally, about 30+ key pharma and biotech companies are working on 30+ pipeline drugs in the Moderate-to-Severe Plaque Psoriasis therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

"Moderate-to-Severe Plaque Psoriasis Pipeline Insight, 2022" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Moderate-to-Severe Plaque Psoriasis Therapeutics Market.

The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).

The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Moderate-to-Severe Plaque Psoriasis Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Moderate-to-Severe Plaque Psoriasis Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Moderate-to-Severe Plaque Psoriasis treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Moderate-to-Severe Plaque Psoriasis market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

DelveInsight's Report covers around 30+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Request for Sample PDF to Understand More About the Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/report-store/moderate-to-severe-plaque-psoriasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Recent Developments in the Moderate-to-Severe Plaque Psoriasis Therapeutics Market
On 09 September 2022, Bristol Myers Squibb (NYSE: BMY) announced that the US FDA had approved Sotyktu™(deucravacitinib) for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. The FDA approval was based on results from the pivotal Phase 3 POETYK PSO-1 and POETYK PSO-2 clinical trials.

Moderate-to-Severe Plaque Psoriasis Therapeutics Analysis
There are approx. 30+ key companies developing therapies for Moderate to Severe Plaque Psoriasis. Currently, Bristol-Myers Squibb has its Moderate to Severe Plaque Psoriasis drug candidates in the most advanced stage of clinical development.

Key Companies in the Moderate to Severe Plaque Psoriasis Therapeutic Market include:
• GC Cell Corporation
• Bioeq GmbH
• Dong-A ST Co., Ltd.
• Can-fite Biopharma
• Bio-thera solutions
• AbbVie
• Sinocelltech
• Jansen research and development
• Innovent Biologics
• Aurigene discovery
• Affibody
• GlaxoSmithKline
• Abcentra
• Bristol-Myers Squibb
• Akeso Biopharma
• Jiangsu Hengrui Medicine
• Nimbus Therapeutics
• Sun Pharmaceutical Industries Limited
• Suzhou Zelgen Biopharmaceuticals
And many others

Moderate to Severe Plaque Psoriasis Emerging Drugs Covered in the report include:
• BMS-986165 (Bristol-Myers Squibb)
• AK111 (Akeso Biopharma)
And many more

Download Sample Pages to Get an in-depth Assessment of the Emerging Therapies and Key Companies:
https://www.delveinsight.com/sample-request/moderate-to-severe-plaque-psoriasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Moderate-to-Severe Plaque Psoriasis Current Treatment Patterns
4. Moderate-to-Severe Plaque Psoriasis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Moderate-to-Severe Plaque Psoriasis Late-Stage Products (Phase-III)
7. Moderate-to-Severe Plaque Psoriasis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Moderate-to-Severe Plaque Psoriasis Discontinued Products
13. Moderate-to-Severe Plaque Psoriasis Product Profiles
14. Moderate-to-Severe Plaque Psoriasis Key Companies
15. Moderate-to-Severe Plaque Psoriasis Key Products
16. Dormant and Discontinued Products
17. Moderate-to-Severe Plaque Psoriasis Unmet Needs
18. Moderate-to-Severe Plaque Psoriasis Future Perspectives
19. Moderate-to-Severe Plaque Psoriasis Analyst Review
20. Appendix
21. Report Methodology
*The table of contents is not exhaustive; the final content may vary.

Request the Sample PDF to Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/moderate-to-severe-plaque-psoriasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Media Contact

Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.